@BitcoinNews@EricTrump@_dsencil@consensus2026 I’d vote “a bit of both.”
Saying no to every big project can hurt workers because jobs, taxes, and innovation don’t magically appear. But big corporations also shouldn’t get unlimited power. Growth is good when the community gets real value from it.
AOC pushed Amazon away. Sanders celebrated no new data centers.
@EricTrump explains to @_dsencil at @Consensus2026:
Reject growth?
Can’t expect jobs or investment.
🔄 Anti-growth policies hurt workers
❤️ Big corporations have too much power
https://t.co/Dya0GDs53y
I can't reply to any messages though
@x@elonmusk@grok
This is an issue with the Android X App...
No account of mine can "reply" to posts right now, so i know it's not a "ban" and or that I am not blocked by anyone
"Failed to send"...
@BitcoinNews@knafo_sarah@_dsencil@ParisBlockWeek 🔘 Maybe — but more privately
I’d still hold BTC, but I’d never make it my public identity.
Sarah Knafo talking about kidnappings for crypto is a harsh reminder that privacy is not paranoia anymore. It’s protection.
Cold wallet, low profile, no loud lifestyle 😆😁
“They cut off a finger.”
MEP @knafo_sarah reacts to the recent wrench attacks targeting Bitcoin entrepreneurs in Paris, telling @_dsencil at @parisblockweek that France needs 100,000 new prison cells.
Hear her full take 👇
We invite you to another monthly AMA with our Core advisor, @100bviking, to discuss all things $FLOKI / $TOKEN!
🗓: Monday, June 1, 8AM UTC
📌: https://t.co/ZLzCfV3mXU
Drop your questions in the form. Each selected question wins $100 USDT on BSC. 👇
https://t.co/vtgP8RYizx
Giveaway for our upcoming X Space with Lucent.
$1,000 USDC for 10 winners - $100 each.
To enter:
• like
• repost
• follow @UseLucentHQ
• reply with one biopharma theme, catalyst, or company you wish investors could track more clearly
GLP-1s, oncology, rare disease, gene therapy, longevity, radiopharma, AI drug discovery, FDA catalysts - all fair.
Lucent is building AI-native biopharma intelligence for one of the hardest markets to read.
Bring a sharp question before the Space.
Winners will be contacted within 7 days after the Space.
@ax1vc@UseLucentHQ@JulianMalinak Radiopharma and rare disease catalysts deserve way better tracking tools.
Small trial updates, FDA designations, manufacturing progress or enrollment delays can completely change a company’s outlook overnight but most investors only notice after the move already happened....
X Space - Thursday, May 28, 5PM UTC
AX1 is partnering with @UseLucentHQ
Lucent is an Alliance alum building in one of the harder corners of investing: biopharma.
Join us with @JulianMalinak, co-founder of Lucent, to discuss why biopharma may need a much better investing interface.
This market moves on FDA decisions, trial readouts, filings, expert debates, and small signals most investors never learn how to read.
A lot of the information is technically public, but public does not mean understandable.
It is scattered and hard to turn into a view before the market already reacts.
Lucent is building for that gap.
AI-native biopharma intelligence that helps investors track catalysts, understand company and asset-level context, and see why a signal may matter.
Set a reminder.
https://t.co/eQtwcKxW4X
@toastpunk Honestly I’d save it for late night food runs during Eid week 🍢 plus maybe buy some coffee because my sleep schedule already surrendered
0x5961189C701F30101d114F5CD8CE975fb4E46D6D